Obeticholic acid for the treatment of primary biliary cirrhosis
Open accessThe DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Abstract
Primary biliary cirrhosis (PBC) is characterized by progressive nonsuppurative destruction of small bile ducts, resulting in intrahepatic cholestasis, fibrosis and ultimately end-stage liver disease. Timely intervention with ursodeoxycholic acid is associated with excellent survival, although approximately one-third of all patients fail to achieve biochemical response, signifying a critical need for additional therapeutic strategies. Obeticholic acid (OCA) is a potent ligand of the nuclear hormone receptor farnesoid X receptor (FXR). Activation of FXR inhibits bile acid synthesis and protects against toxic accumulation in models of cholestasis and facilitates hepatic regeneration in preclinical studies. Data from recent Phase II and III controlled trials suggest a therapeutic impact of OCA in PBC biochemical nonresponders, as evidenced by change in proven laboratory surrogates of long-term outcome. Dose-dependent pruritus is a common adverse effect, but may be overcome through dose-titration. Longer term studies are needed with focus on safety and long-term clinical efficacy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237 · cited 3×
“However, it is unclear whether attenuation in itch severity over time (10 mg group) was specifically due to symptom-specific intervention or due to development of OCA tolerance, and data pertaining to cholestyramine initiation date/duration are currently unavailable.[63] In addition to being a selective ligand for FXR…”
BackgroundFibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis
Inagaki, T., Choi, M., Moschetta, A., Peng, L., Cummins, C. L., McDonald, J. G., Luo, G., Jones, S. A., Goodwin, B., Richardson, J. A., et al. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2005.09.001 · Cited by 1,865
Targeted Disruption of the Nuclear Receptor FXR/BAR Impairs Bile Acid and Lipid Homeostasis
Sinal, C. J., Tohkin, M., Miyata, M., Ward, J. M., Lambert, G., & Gonzalez, F. J. (2000) · Cell · doi:10.1016/s0092-8674(00)00062-3 · Cited by 1,819 · cited 3×
“[62, 63] Although FXR response elements exist in the proximal region of the human MDR3 promoter (MDR3 mRNA levels increasing following FXR ligation,[64]) Fxr knockout mice still respond to a cholic acid-rich diet with an increase in transcription of Mdr2 (the murine ortholog of MDR3,[65]) Indeed, activation of the nuc…”
BackgroundEASL Clinical Practice Guidelines: management of cholestatic liver diseases
European Association for the Study of the Liver (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.04.009 · Cited by 1,729
Pleiotropic Roles of Bile Acids in Metabolism
de Aguiar Vallim, T. Q., Tarling, E. J., & Edwards, P. A. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.03.013 · Cited by 1,209
Lindor, K. D., Gershwin, E. M., Poupon, R., Kaplan, M., Bergasa, N. V., & Heathcote, J. E. (2009) · Hepatology · doi:10.1002/hep.22906 · Cited by 1,099
Gadaleta, R. M., van Erpecum, K. J., Oldenburg, B., Willemsen, E. C. L., Renooij, W., Murzilli, S., Klomp, L. W. J., Siersema, P. D., Schipper, M. E. I., Danese, S., et al. (2011) · Gut · doi:10.1136/gut.2010.212159 · Cited by 870
Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR
Calkin, A. C., & Tontonoz, P. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3312 · Cited by 779
Parés, A., Caballería, L., & Rodés, J. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.12.029 · Cited by 756 · cited 2×
“001 [38]) however still remains lower than age- and sex-matched control populations in the current era.[13,14,43] On-treatment liver biochemical changes are variable in PBC, with some patients experiencing complete normalization and others only minor improvements.”
BackgroundPellicciari, R., Fiorucci, S., Camaioni, E., Clerici, C., Costantino, G., Maloney, P. R., Morelli, A., Parks, D. J., & Willson, T. M. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm025529g · Cited by 743 · cited 2×
“[21] Chenodeoxycholic acid (CDCA) and its semisynthetic analog obeticholic acid (OCA) are selective ligands for FXR, with the latter illustrating exponential activation potency relative to its endogenous counterpart (Figure 1).[22] OCA also induces expression of fibroblast growth factor (FGF)-19 which could plausibly…”
BackgroundBile acid receptors as targets for drug development
Schaap, F. G., Trauner, M., & Jansen, P. L. M. (2014) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.151 · Cited by 696 · cited 4×
“However, unlike UDCA, which operates at a post-translational level, FXR-signaling directly regulates genes involved in bile acid synthesis, secretion, transportation, absorption and detoxification.[21] Chenodeoxycholic acid (CDCA) and its semisynthetic analog obeticholic acid (OCA) are selective ligands for FXR, with…”
BackgroundInfluentialBiochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis
Corpechot, C., Abenavoli, L., Rabahi, N., Chrétien, Y., Andréani, T., Johanet, C., Chazouillères, O., & Poupon, R. (2008) · Hepatology · doi:10.1002/hep.22428 · Cited by 646
Farnesoid X receptor antagonizes nuclear factor κB in hepatic inflammatory response
Wang, Y.-D., Chen, W.-D., Wang, M., Yu, D., Forman, B. M., & Huang, W. (2008) · Hepatology · doi:10.1002/hep.22519 · Cited by 639
FGF19 as a Postprandial, Insulin-Independent Activator of Hepatic Protein and Glycogen Synthesis
Kir, S., Beddow, S. A., Samuel, V. T., Miller, P., Previs, S. F., Suino-Powell, K., Xu, H. E., Shulman, G. I., Kliewer, S. A., & Mangelsdorf, D. J. (2011) · Science · doi:10.1126/science.1198363 · Cited by 637
Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: A systematic review
Boonstra, K., Beuers, U., & Ponsioen, C. Y. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.10.025 · Cited by 632
Hirschfield, G. M., Mason, A., Luketic, V., Lindor, K., Gordon, S. C., Mayo, M., Kowdley, K. V., Vincent, C., Bodhenheimer, H. C., Parés, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2014.12.005 · Cited by 576 · cited 9×
“[38] Results from the first randomized, double-blind controlled trial in PBC were recently published, wherein the therapeutic efficacy of UDCA and three doses of OCA (10, 25 and 50 mg/ www.tandfonline.com 17 day) compared against UDCA/placebo.”
BackgroundResultInfluentialSelf-citationNew paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond
Beuers, U., Trauner, M., Jansen, P., & Poupon, R. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.02.023 · Cited by 537 · cited 1×
“Anticholestatic effects of UDCA are predominantly dependent on Ca-dependent signaling (inositol-triphosphate receptor and protein kinase), with well-known antiapoptotic functions conferring additional hepatoprotective and cholangioprotective benefit.[53, 54] The expression of certain other hepatocellular transporter g…”
BackgroundLammers, W. J., van Buuren, H. R., Hirschfield, G. M., Janssen, H. L. A., Invernizzi, P., Mason, A. L., Ponsioen, C. Y., Floreani, A., Corpechot, C., Mayo, M. J., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.08.029 · Cited by 498 · cited 3×
“001 [38]) however still remains lower than age- and sex-matched control populations in the current era.”
BackgroundInfluentialSelf-citationYang, F., Huang, X., Yi, T., Yen, Y., Moore, D. D., & Huang, W. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-1078 · Cited by 488
Lammers, W. J., Hirschfield, G. M., Corpechot, C., Nevens, F., Lindor, K. D., Janssen, H. L. A., Floreani, A., Ponsioen, C. Y., Mayo, M. J., Invernizzi, P., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.07.061 · Cited by 441
Self-citationAhn, S., Jang, S. J., Shim, J. H., Kim, D., Hong, S., Sung, C. O., Baek, D., Haq, F., Ansari, A. A., Lee, S. Y., et al. (2014) · Hepatology · doi:10.1002/hep.27198 · Cited by 424
Drug Insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis
Beuers, U. (2006) · Nature Clinical Practice Gastroenterology & Hepatology · doi:10.1038/ncpgasthep0521 · Cited by 417 · cited 1×
“[5–9] Presently, the mainstay of treatment is ursodeoxycholic acid (UDCA), which in addition to stimulating hepatobiliary secretions is a potent intracellular signaling molecule, inducing choleresis through MAPK and integrindependent mechanisms;[10] as well as protecting epithelia from ‘toxic’ effects of low pH bile a…”
BackgroundCarbone, M., Mells, G. F., Pells, G., Dawwas, M. F., Newton, J. L., Heneghan, M. A., Neuberger, J. M., Day, D. B., Ducker, S. J., Sandford, R. N., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2012.12.005 · Cited by 386
Kumagi, T., Guindi, M., Fischer, S. E., Arenovich, T., Abdalian, R., Coltescu, C., Heathcote, J. E., & Hirschfield, G. M. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2010.216 · Cited by 372
Self-citationA Mouse Model of Hepatocellular Carcinoma
Nicholes, K., Guillet, S., Tomlinson, E., Hillan, K., Wright, B., Frantz, G. D., Pham, T. A., Dillard-Telm, L., Tsai, S. P., Stephan, J.-P., et al. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)61177-7 · Cited by 359 · cited 2×
“For instance, the development of HCC in aged Fxr null mice can be prevented by re-expressing a constitutive active form of FXR in the intestine; [101] conversely, FGF19 transgenic mice are seen to develop spontaneous HCC,[102] and FGF19 amplifications have been implicated in driving hepatic carcinogenesis in man.”
BackgroundSpontaneous hepatocarcinogenesis in farnesoid X receptor-null mice
Kim, I., Morimura, K., Shah, Y., Yang, Q., Ward, J. M., & Gonzalez, F. J. (2007) · Carcinogenesis · doi:10.1093/carcin/bgl249 · Cited by 357
Carbone, M., Sharp, S. J., Flack, S., Paximadas, D., Spiess, K., Adgey, C., Griffiths, L., Lim, R., Trembling, P., Williamson, K., et al. (2016) · Hepatology · doi:10.1002/hep.28017 · Cited by 354
Self-citationCorpechot, C., Carrat, F., Poujol-Robert, A., Gaouar, F., Wendum, D., Chazouillères, O., & Poupon, R. (2012) · Hepatology · doi:10.1002/hep.25599 · Cited by 351
Serum bilirubin: a prognostic factor in primary biliary cirrhosis
Shapiro, J. M., Smith, H., & Schaffner, F. (1979) · Gut · doi:10.1136/gut.20.2.137 · Cited by 319
Ghonem, N. S., Assis, D. N., & Boyer, J. L. (2015) · Hepatology · doi:10.1002/hep.27744 · Cited by 317
Goulis, J., Leandro, G., & Burroughs, A. K. (1999) · The Lancet · doi:10.1016/s0140-6736(98)11293-x · Cited by 315 · cited 1×
“Ursodeoxycholic acid is currently the only approved drug for treating PBC, demonstrating consistent evidence in improving liver biochemistry [40, 41] and a lower progression rate from early stage disease to extensive fibrosis/cirrhosis compared with placebo in clinical trials (7 vs 35% per year; p < 0.”
BackgroundThe immunobiology and pathophysiology of primary biliary cirrhosis
Hirschfield, G. M., & Gershwin, M. E. (2013) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-020712-164014 · Cited by 315
Self-citationHohenester, S., de Buy Wenniger, L. M., Paulusma, C. C., van Vliet, S. J., Jefferson, D. M., Oude Elferink, R. P., & Beuers, U. (2012) · Hepatology · doi:10.1002/hep.24691 · Cited by 315
Pathogenesis of cholestatic liver disease and therapeutic approaches
Hirschfield, G. M., Heathcote, E. J., & Gershwin, M. E. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.09.004 · Cited by 287
Self-citationModica, S., Petruzzelli, M., Bellafante, E., Murzilli, S., Salvatore, L., Celli, N., Di Tullio, G., Palasciano, G., Moustafa, T., Halilbasic, E., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2011.10.028 · Cited by 275
Verbeke, L., Farre, R., Trebicka, J., Komuta, M., Roskams, T., Klein, S., Elst, I. V., Windmolders, P., Vanuytsel, T., Nevens, F., et al. (2014) · Hepatology · doi:10.1002/hep.26939 · Cited by 258 · cited 1×
“FXR agonism has also been shown to reduce portal hypertension in vivo through a direct action on endothelial nitric oxide synthase (eNOS) activation, inhibition of endothelin-1mediated HSC contraction and consequently a reduction in intrahepatic vascular resistance.[25, 81] This observation is of particular relevance…”
BackgroundImpact of primary biliary cirrhosis on perceived quality of life: The UK-PBC national study
Mells, G. F., Pells, G., Newton, J. L., Bathgate, A. J., Burroughs, A. K., Heneghan, M. A., Neuberger, J. M., Day, D. B., Ducker, S. J., Sandford, R. N., et al. (2013) · Hepatology · doi:10.1002/hep.26365 · Cited by 227
Pruritus in cholestasis: facts and fiction
Beuers, U., Kremer, A. E., Bolier, R., & Elferink, R. P. J. O. (2014) · Hepatology · doi:10.1002/hep.26909 · Cited by 225 · cited 1×
“Bile salts may also lead to activation and degranulation of mast cells,[92] although a wealth of research effort has failed to illustrate causal relationships between pruritus and either serum bile salt concentration or histaminergic activity.[93] Moreover, antihistamines have historically proven ineffective in the tr…”
BackgroundYang, C.-Y., Ma, X., Tsuneyama, K., Huang, S., Takahashi, T., Chalasani, N. P., Bowlus, C. L., Yang, G.-X., Leung, P. S. C., Ansari, A. A., et al. (2014) · Hepatology · doi:10.1002/hep.26979 · Cited by 213
Time course of histological progression in primary biliary cirrhosis
Locke, G. R., Therneau, T. M., Ludwig, J., Dickson, E. R., & Lindor, K. D. (1996) · Hepatology · doi:10.1002/hep.510230108 · Cited by 184 · cited 1×
“[32, 33] Advanced histological stage is a clear determinant of poor clinical outcome and in an era where liver biopsy was the norm and effective therapy lacking, the median time to develop extensive fibrosis was ~2 years and probability of remaining in early stage disease <30% over a 4-year period.[34, 35] However, th…”
BackgroundFiorucci, S., Rizzo, G., Antonelli, E., Renga, B., Mencarelli, A., Riccardi, L., Orlandi, S., Pruzanski, M., Morelli, A., & Pellicciari, R. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.084905 · Cited by 183
Trivedi, P. J., Lammers, W. J., van Buuren, H. R., Parés, A., Floreani, A., Janssen, H. L. A., Invernizzi, P., Battezzati, P. M., Ponsioen, C. Y., Corpechot, C., et al. (2016) · Gut · doi:10.1136/gutjnl-2014-308351 · Cited by 178 · cited 2×
“[104] These discrepant findings support the need for appropriate safety monitoring of drugs that modulate the FXR axis; particularly, given that biochemical nonresponders in PBC represent a group in which HCC risk is greatest.[105] The requirement for additional medical treatment in PBC is clearly recognized; and in a…”
BackgroundResultSelf-citationMencarelli, A., Renga, B., Migliorati, M., Cipriani, S., Distrutti, E., Santucci, L., & Fiorucci, S. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901347 · Cited by 177
Fickert, P., Fuchsbichler, A., Moustafa, T., Wagner, M., Zollner, G., Halilbasic, E., Stöger, U., Arrese, M., Pizarro, M., Solís, N., et al. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.090114 · Cited by 169 · cited 1×
“report cell-type-specific expression of FXR as relatively low in mouse and human HSC and hepatic MFB when compared with that observed in whole liver.[80] Nevertheless, Fxr loss significantly attenuated liver fibrosis, specifically in models of biliary (BDL, or dietary 3,5-diethoxycarbonyl-1,4-dihydrocollidine applicat…”
BackgroundCorpechot, C., Carrat, F., Poupon, R., & Poupon, R. (2002) · Gastroenterology · doi:10.1053/gast.2002.31880 · Cited by 169
Trivedi, P. J., Bruns, T., Cheung, A., Li, K.-K., Kittler, C., Kumagi, T., Shah, H., Corbett, C., Al-Harthy, N., Acarsu, U., et al. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.01.029 · Cited by 132 · cited 2×
“Assessment of further surrogates of clinical outcome (including for instance AST/platelet ratio, liver stiffness measurements derived via transient elastography) would be of additional clinical benefit in this regard.[18, 88]”
BackgroundSelf-citationKeitel, V., Ullmer, C., & Häussinger, D. (2010) · Biological Chemistry · doi:10.1515/bc.2010.077 · Cited by 129
Degirolamo, C., Modica, S., Vacca, M., Di Tullio, G., Morgano, A., D'Orazio, A., Kannisto, K., Parini, P., & Moschetta, A. (2015) · Hepatology · doi:10.1002/hep.27274 · Cited by 121
Lens, S., Leoz, M., Nazal, L., Bruguera, M., & Parés, A. (2014) · Liver International · doi:10.1111/liv.12290 · Cited by 107 · cited 1×
“Similar results have also been garnered with regard to bezafibrate (PPARα/Δ/Γ agonist), which has the added benefit of alleviating pruritus of cholestasis.[108, 109] Unfortunately, many studies of fibrates are limited in terms of patient number follow-up (some <8 weeks in duration), lack of appropriate controls, appli…”
ResultGrigorian, A. Y., Mardini, H. E., Corpechot, C., Poupon, R., & Levy, C. (2015) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2015.02.011 · Cited by 99
Jones, D. E., Al-Rifai, A., Frith, J., Patanwala, I., & Newton, J. L. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.05.026 · Cited by 91 · cited 1×
“001 [38]) however still remains lower than age- and sex-matched control populations in the current era.[13,14,43] On-treatment liver biochemical changes are variable in PBC, with some patients experiencing complete normalization and others only minor improvements.”
BackgroundHuet, P., Vincent, C., Deslaurier, J., Coté, J., Matsutami, S., Boileau, R., & Huet–van Kerckvoorde, J. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.07.019 · Cited by 84
Good Maternal and Fetal Outcomes for Pregnant Women With Primary Biliary Cirrhosis
Trivedi, P. J., Kumagi, T., Al-Harthy, N., Coltescu, C., Ward, S., Cheung, A., & Hirschfield, G. M. (2014) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2013.11.030 · Cited by 77
Self-citationα5β1-integrins are sensors for tauroursodeoxycholic acid in hepatocytes
Gohlke, H., Schmitz, B., Sommerfeld, A., Reinehr, R., & Häussinger, D. (2013) · Hepatology · doi:10.1002/hep.25992 · Cited by 77 · cited 1×
“[5–9] Presently, the mainstay of treatment is ursodeoxycholic acid (UDCA), which in addition to stimulating hepatobiliary secretions is a potent intracellular signaling molecule, inducing choleresis through MAPK and integrindependent mechanisms;[10] as well as protecting epithelia from ‘toxic’ effects of low pH bile a…”
BackgroundUnmet clinical need in autoimmune liver diseases
Dyson, J. K., Webb, G., Hirschfield, G. M., Lohse, A., Beuers, U., Lindor, K., & Jones, D. E. J. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2014.09.010 · Cited by 66
Self-citationInhibition of endothelin-1-mediated contraction of hepatic stellate cells by FXR ligand
Li, J., Kuruba, R., Wilson, A., Gao, X., Zhang, Y., & Li, S. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013955 · Cited by 66
Cited by
Hirschfield, G. M., Dyson, J. K., Alexander, G. J. M., Chapman, M. H., Collier, J., Hübscher, S., Patanwala, I., Pereira, S. P., Thain, C., Thorburn, D., et al. (2018) · Gut · doi:10.1136/gutjnl-2017-315259 · Cited by 362
Self-citationObeticholic acid-a new therapy in PBC and NASH
Chapman, R. W., & Lynch, K. D. (2020) · British Medical Bulletin · doi:10.1093/bmb/ldaa006 · Cited by 116
Complications, symptoms, quality of life and pregnancy in cholestatic liver disease
Zakharia, K., Tabibian, A., Lindor, K. D., & Tabibian, J. H. (2018) · Liver International · doi:10.1111/liv.13591 · Cited by 42
Metadata
- Authors
- Trivedi, P. J., Hirschfield, G. M., & Gershwin, M. E.
- Venue
- Expert Review of Clinical Pharmacology
- Publisher
- Informa UK Limited
- Published
- 2015-11-07
- Volume
- 9
- Issue
- 1
- Pages
- 13-26
- ISSN
- 1751-2433 (ISSN-L)
- 1751-2441
- OpenAlex
- W2148535164
- Cited by
- 63
- References
- 56
- FWCI
- 4.43
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.